Recall(New to the series?)
Dual agonists combine GLP-1R activation with either GIPR (GIP) or GCGR (glucagon). GIP synergizes with GLP-1 in fat tissue and the brain to amplify weight loss. Glucagon raises energy expenditure and drives hepatic fat mobilization. For the full receptor breakdown, see The Receptor Game.
The dual agonist family was built around one question: what happens when you activate two receptors instead of one? The answer, once tirzepatide hit Phase 3, was clear — you break the 15% weight loss ceiling that single GLP-1 agonists couldn't get past.
The family splits into two mechanistic branches that take different theories of how to do that.
The two branches
GLP-1 + GIP is the commercially proven branch. Tirzepatide activates both GLP-1R and GIPR with roughly equal potency. The GIP mechanism was controversial going in — early research suggested GIP might oppose weight loss. Tirzepatide's ~21% weight loss in SURMOUNT-1 ended that debate. GIPR activation in fat tissue and the brain amplifies GLP-1's appetite signal through pathways that are still being characterized mechanistically.
GLP-1 + glucagon is the mechanistically distinct branch. Glucagon is canonically a glucose-raising hormone — the last thing you'd think to add to a diabetes or obesity drug. But GCGR activation also raises resting energy expenditure and drives hepatic fat oxidation, effects that GLP-1 alone doesn't have. The glucagon component theoretically counters the metabolic rate adaptation that limits weight loss over time, and it directly targets the liver — which is why this branch is particularly relevant for MASH (metabolic dysfunction-associated steatohepatitis).
The key difference between the branches: GLP-1/GIP amplifies appetite suppression, GLP-1/glucagon adds metabolic rate. They're not redundant — they're solving different parts of the weight loss problem.
What defines dual agonism
Breaking the ceiling — dual agonists reliably reach 19–21% weight loss in well-powered Phase 3 trials, vs ~15% for single GLP-1 agonists. The SURMOUNT-5 head-to-head (tirzepatide vs semaglutide 2.4mg, 2025) confirmed ~47% greater relative weight loss for the dual agonist.
The glucagon balance problem — GCGR activation raises blood glucose via hepatic glucose production, which partially opposes GLP-1's insulin-stimulating effect. GLP-1/glucagon dual drugs require careful dose titration to balance these competing effects, particularly in non-diabetic patients. GLP-1/GIP drugs don't have this complication since GIPR doesn't directly affect glucose in the same way.
MASH as an indication — the GLP-1/glucagon branch has the strongest mechanistic case for liver disease. Glucagon drives hepatic fat oxidation directly. Survodutide's Phase 2 MASH data (~67% resolution without fibrosis worsening) reflects this. GLP-1/GIP drugs produce MASH improvement through weight loss alone; GLP-1/glucagon drugs add a direct liver mechanism on top of that.
Drugs in this family
GLP-1 / GIP
- Tirzepatide — Mounjaro / Zepbound — approved, current efficacy standard
- VK2735 — Phase 3, subcutaneous and oral formulations
- Olatorepatide — Phase 3, Hansoh / Regeneron
GLP-1 / Glucagon
- Survodutide — Phase 3, leading GLP-1/glucagon dual, strong MASH data
- Pemvidutide — Phase 2/3, MASH-focused
- Mazdutide — China-approved 2025, first GLP-1/glucagon approval globally
Summary(The dual agonist picture)
Dual agonism reliably outperforms single GLP-1 agonism. Tirzepatide proved the GLP-1/GIP approach at commercial scale. The GLP-1/glucagon branch adds energy expenditure and liver targeting that GIP doesn't provide — particularly relevant for MASH. The head-to-head between the two branches is the open question this family will answer over the next 2–3 years.